Podium to Practice: ESMO® 2025 – Melanoma: PRAME

Podium to Practice: ESMO® 2025 – Melanoma: PRAME

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Teresa Petrella

Icon Chair Speaker

Speakers

Dr. Marcus Butler

Prof. Caroline Robert

Studies / Trials Discussed

1600O – Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial

Studies/trials discussed:

1600O – Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial
Tagged